

**Article Corrected**

Scott LJ, Yang LPH, Lyseng-Williamson KA. Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer. *Drugs Aging* 2012; 29 (3): 243-8

**Correction Made**

**Page 244, table I, ‘Clinical benefits’ subsection:** The third sentence, which previously read:

“Only second-line therapy available that prolongs overall survival”

has now been corrected as follows:

“Only second-line hormonal therapy currently shown to prolong overall survival”

**Note**

All online versions of this article have been updated to reflect this correction.